New drug combo targets aggressive brain cancer in early trial
Disease control
Not yet recruiting
This early-phase study tests a new drug called MT-125 alongside standard chemoradiation in people newly diagnosed with a specific type of glioblastoma (MGMT methylated). The goal is to find a safe dose and see how well the body handles it. About 36 adults will take part, with the…
Phase: PHASE1, PHASE2 • Sponsor: Myosin Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC